In this video, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, comments on the lack of a clear definition of suboptimal response to ruxolitinib treatment in patients with myelofibrosis (MF), emphasizing the importance of patient-physician discussions to identify persistent symptoms, which will aid in selecting an alternative therapy. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
